Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

被引：0
|
作者：
Henri Bounameaux
A. John Camm
机构：
[1] University Hospital of Geneva,Department of Internal Medicine
[2] University Medical Center (CMU),Faculty of Medicine, Dean’s Office
[3] St George’s University of London,Division of Clinical Sciences
来源：
Drugs | 2014年 / 74卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1455 / 1455
相关论文
共 50 条
  • [31] An oral anticoagulant with direct Factor-Xa-inhibitor
    Weiche, Iris
    NERVENHEILKUNDE, 2010, 29 (05) : 320 - 320
  • [32] Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor
    Abrams, Paris J.
    Emerson, Christopher R.
    PHARMACOTHERAPY, 2009, 29 (02): : 167 - 181
  • [33] Rivaroxaban, the first oral, direct factor Xa inhibitor
    Fassiadis, Nicholas
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (18) : 2945 - 2946
  • [34] Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa inhibitor edoxaban
    Morishima, Yoshiyuki
    Shibano, Toshiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 30P - 30P
  • [35] Comparison of the effects of edoxaban, an oral factor Xa inhibitor, and other anticoagulants on thrombin generation
    Mendell, J.
    Li, Y.
    Samama, M. M.
    Halim, A-B
    Song, S.
    Depasse, F.
    Kunitada, S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 575 - 575
  • [36] AN ORAL FACTOR XA INHIBITOR, EDOXABAN, ALLEVIATES DIABETIC NEPHROPATHY IN MICE LACKING eNOS
    Oe, Yuji
    Fushima, Tomofumi
    Sato, Emiko
    Sato, Hiroshi
    Ito, Sadayoshi
    Takahashi, Nobuyuki
    JOURNAL OF HYPERTENSION, 2016, 34 : E102 - E102
  • [37] Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans
    Bathala, Mohinder S.
    Masumoto, Hiroshi
    Oguma, Toshihiro
    He, Ling
    Lowrie, Chris
    Mendell, Jeanne
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (12) : 2250 - 2255
  • [38] Rivaroxaban: A New Oral Factor Xa Inhibitor
    Perzborn, Elisabeth
    Roehrig, Susanne
    Straub, Alexander
    Kubitza, Dagmar
    Mueck, Wolfgang
    Laux, Volker
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (03) : 376 - U24
  • [39] Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates
    Fukuda, Toshio
    Tsuji, Naoki
    Honda, Yuko
    Kamisato, Chikako
    Morishima, Yoshiyuki
    Shibano, Toshiro
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (06) : 1062 - 1068
  • [40] Rivaroxaban An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism
    Chen, Terry
    Lam, Sum
    CARDIOLOGY IN REVIEW, 2009, 17 (04) : 192 - 197
12345